The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Novartis for Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression.   IgAN is a rare but serious kidney disorder affecting millions worldwide. Despite being a progressive condition, treatment options have been limited. Fabhalta’s approval marks a potential breakthrough in addr...